Oxford Immunotec Global (NASDAQ:OXFD) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Thursday.
Several other equities analysts have also commented on the company. BTIG Research set a $21.00 price target on Oxford Immunotec Global and gave the company a “buy” rating in a research note on Monday, December 18th. Zacks Investment Research lowered Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research note on Saturday, November 4th. Robert W. Baird reissued a “buy” rating and set a $20.00 target price on shares of Oxford Immunotec Global in a research note on Wednesday, November 1st. ValuEngine lowered Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research note on Tuesday, October 31st. Finally, Piper Jaffray Companies decreased their target price on Oxford Immunotec Global from $26.00 to $19.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 31st. Three research analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $19.75.
Oxford Immunotec Global (OXFD) opened at $11.51 on Thursday. Oxford Immunotec Global has a 12 month low of $10.81 and a 12 month high of $19.51. The company has a market capitalization of $292.21, a price-to-earnings ratio of -5.73 and a beta of -0.09. The company has a quick ratio of 4.30, a current ratio of 4.72 and a debt-to-equity ratio of 0.38.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Voya Investment Management LLC lifted its stake in Oxford Immunotec Global by 16.0% during the 2nd quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock worth $224,000 after acquiring an additional 1,845 shares in the last quarter. Alliancebernstein L.P. acquired a new position in Oxford Immunotec Global during the 2nd quarter worth about $247,000. Asymmetry Capital Management L.P. purchased a new stake in Oxford Immunotec Global during the 2nd quarter worth about $273,000. The Manufacturers Life Insurance Company increased its holdings in Oxford Immunotec Global by 8.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,631 shares of the company’s stock worth $313,000 after purchasing an additional 1,500 shares during the period. Finally, Rhumbline Advisers increased its holdings in Oxford Immunotec Global by 9.1% during the 2nd quarter. Rhumbline Advisers now owns 24,500 shares of the company’s stock worth $412,000 after purchasing an additional 2,053 shares during the period. 89.35% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Oxford Immunotec Global (OXFD) Stock Rating Lowered by BidaskClub” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.chaffeybreeze.com/2018/01/11/oxford-immunotec-global-oxfd-stock-rating-lowered-by-bidaskclub.html.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.